CTSO Valuation

Cytosorbents Corp

Add to Watchlist

Advanced Chart

1.000

-0.02(-1.961%)1D

Overview
Forecast
Valuation
Earnings

CTSO Relative Valuation

CTSO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTSO is overvalued; if below, it's undervalued.

Historical Valuation

Cytosorbents Corp (CTSO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.60 is considered Undervalued compared with the five-year average of -13.34. The fair price of Cytosorbents Corp (CTSO) is between 1.32 to 4.12 according to relative valuation methord. Compared to the current price of 1.02 USD , Cytosorbents Corp is Undervalued By 22.96%.

Relative Value

Fair Zone

1.32-4.12

Current Price：1.02

22.96%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

4.39

P/B

Median3y

3.52

Median5y

3.97

-21.25

FCF Yield

Median3y

-34.80

Median5y

-23.79

Competitors Valuation Multiple

The average P/S ratio for CTSO's competitors is 5.01, providing a benchmark for relative valuation. Cytosorbents Corp Corp (CTSO) exhibits a P/S ratio of 1.54, which is -69.30% above the industry average. Given its robust revenue growth of -2.92%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap